Jointly presented by the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing

Supported by educational grants from Bristol-Myers Squibb, Gilead Sciences, Inc., and Merck & Co., Inc.

dkb header

New HCV DAA Regimens, Retreatment and Optimizing Treatment of Genotype 2/3 Infection

a podcast discussion with David L. Wyles, MD dkb icon

You are using an outdated browser. Please upgrade your browser or activate Google Chrome Frame to improve your experience.